Male Reproduction and Aging.

The syndromic prevalence of late-onset hypogonadism (age-related low testosterone) is quite low based on well-conducted population studies.

• Recent publications of well-conducted population studies informed this finding
• The condition is referred to as 'late-onset hypogonadism' or 'age-related low testosterone'
• The paper characterizes the prevalence as 'quite low' based on syndromic definition requiring both low testosterone levels and associated symptoms

Testosterone therapy in middle-aged and older men with age-related testosterone decline produces modest improvements in sexual function, mood, volumetric bone density, and anemia.

• Evidence comes from 'several well-conducted trials in middle-aged and older men'
• Efficacy is characterized as 'modest'
• Specific outcomes with demonstrated improvement include sexual function, mood, volumetric bone density, and anemia
• The findings are based on men with age-related decline in testosterone levels specifically

The effect of testosterone therapy on prostate cancer risk and major adverse cardiovascular events in older men remains unclear.

• The paper identifies prostate cancer risk and major adverse cardiovascular events as the two key areas of uncertainty
• Select older men might benefit from testosterone therapy despite these uncertainties
• The ongoing TRAVERSE trial is expected to 'provide important insights into these risks'
• The unclear risk profile limits broad recommendations for testosterone therapy in aging men

The TRAVERSE trial is an ongoing study expected to provide important insights into cardiovascular and prostate cancer risks of testosterone therapy.

• TRAVERSE is described as an 'ongoing' trial at the time of publication
• The trial is anticipated to address both prostate cancer risk and major adverse cardiovascular events
• Results are characterized as likely to 'provide important insights into these risks'
• The trial focuses on middle-aged and older men receiving testosterone therapy